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A b s t r a c t
Background: Multiple randomised clinical trials have proven that cardiac resynchronisation therapy (CRT) reduces morbidity 
and mortality in appropriately selected patients with congestive heart failure and is recommended for such patients as per 
the European Society of Cardiology guidelines. 
Aim: In this paper we compare the indications and demographics in cardiac resynchronisation recipients in Poland and other 
European countries.
Methods: In 2015 and 2016, physicians from 42 European countries participated in the second edition of the European 
Cardiac Resynchronisation Therapy Survey. For 14 months, 288 implanting centres gathered data regarding demography, 
indications, implanting methods, and guidance compatibility from 11,088 patients receiving CRT. 
Results: The survey revealed that a vast group of patients were eligible for CRT implantation (although some of them with rela-
tively weak guidance recommendations) and showed essential variety in clinical practice when national data were benchmarked.
Conclusions: The population of CRT recipients in Poland and other European countries did not differ in terms of demographic 
and clinical characteristics. In most cases, indications for CRT were in accordance with the guidelines; however some devices 
were implanted in patients beyond the guideline recommendations. For these procedures, the decision regarding CRT im-
plantation relies mainly on the physicians’ experience.
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INTRODUCTION
The incidence of heart failure (HF) approaches five to ten 
cases per 1000 people per year, and the prevalence can be 
estimated as 1% to 2% of the adult population in developed 
countries, rising to 10% among people over 70 years of age [1, 2]. 
Throughout the last decades, advancements in therapies and 
their implementation have improved survival and reduced the 
hospitalisation rate in patients with congestive heart failure 
(CHF). One of the treatments, cardiac resynchronisation therapy 
(CRT), supports cardiac performance in appropriately selected 
patients, improves symptoms and well-being, and reduces 
morbidity and mortality [3]. A total of 14 randomised clinical 
trials (RCTs), involving 4420 patients proved that CRT decreased 
hospitalisation by 37% and all-cause mortality by 22% [4].
In 1994, Serge Cazeau, a cardiologist at Val d’Or Surgical 
Centre in St. Cloud, France, implanted the first four-chamber 
pacing device in a patient with severe CHF [5]. In 2005, 
CRT was included in the European Society of Cardiology 
(ESC) guidelines. Since 2011, every year the average CRT 
implantation rate in western and central Europe was approxi-
mately 140 units per million population, with an advantage of 
CRT-defibrillators (CRT-D) over CRT-pacemakers (CRT-P) [6]. 
In Poland, since Professor Kutarski implanted the first CRT in 
1998, the method has evolved rapidly, reached an important 
position and was a subject of multiple observations [7].
The aim of CRT is to restore atrioventricular as well as 
inter- and intraventricular synchrony via three leads positioned 
in the right atrium, right ventricle (RV), and left ventricle (LV) 
through the coronary sinus tributary.
Continuous biventricular pacing prevents blockade in the 
cardiac conduction system. CRT improves the LV function, 
reduces functional mitral regurgitation, and induces LV reverse 
remodelling, as shown by an increase in LV filling time and 
left ventricular ejection fraction (LVEF) and a decrease in LV 
end-diastolic and end-systolic volumes, mitral regurgitation, 
and septal dyskinesis [8].
Combined data of sub-groups of patients from the COM-
PANION, CARE-HF, MADIT-CRT, REVERSE, and RAFT trials 
proved that CRT is most beneficial to symptomatic patients 
(New York Heart Association [NYHA] class II–IV) with com-
plete left bundle branch block (LBBB), QRS duration ≥ 150 ms, 
and severely depressed LVEF ≤ 35% [6]. Therefore, the cur-
rent guidelines give strong recommendations for CRT in such 
patients, who do not respond sufficiently to medical therapy.
In 2015, two ESC Associations, the European Heart 
Rhythm Society (EHRA) and the Heart Failure Association 
(HFA), formed the European Cardiac Resynchronisation 
Therapy Survey II, a 15-month initiative (from October 
2015 to December 2016) designed to collect a large volume 
of clinical and demographic data on the delivery of CRT in 
European countries [9, 10]. In this paper we present the main 
differences between the CRT recipients in Poland and other 
European countries.
METHODS
Thanks to the efforts of medical teams from 288 centres, the 
survey gathered data from 42 countries involving 11,088 pa-
tients and provided information permitting centres and coun-
tries to benchmark their practice with international practice.
After providing general information on the implanting 
centre (facility type, size, operator speciality), each hospital 
was asked to complete an electronic case report form on 
consecutive patients who were referred for CRT implanta-
tion [11]. The electronic case report form collected data on 
patients’ characteristics, examinations, indications for CRT, 
implantation procedures, and short-term outcome including 
adverse events and complications. Information on longer-term 
outcome was not collected.
The survey was created to investigate only new CRT im-
plantations (either CRT-P or CRT-D), including both successful 
and unsuccessful procedures. This also included upgrades 
from previously implanted cardioverter-defibrillators (ICDs) 
or permanent pacemakers.
Poland provided essential data on 1241 patients with 
CRT, which comprised 11.2% of the whole survey group. In 
the present study, Polish patients were compared with the 
control group of 9847 patients from all other participating 
countries in terms of each available demographic and pro-
cedural parameter.
Ethical approval and written, informed consent were 
obtained according to the rules for clinical investigations in 
each participating country at the initiation of the study.
Statistical analysis
Absolute numbers and percentages were shown for categori-
cal variables to describe the patient population, and means 
(with standard deviations) or medians (with interquartile 
range) were used for continuous variables. Categorical 
variables were compared between subgroups by the c2 test 
and continuous variables (numerical values) by the Mann- 
-Whitney-Wilcoxon test.
A significance level of p < 0.05 was assumed for the 
statistical tests. All statistical analyses were performed using 
SAS statistical software (version 9.1, Cary, NC, USA).
RESULTS
A total of 1192 devices were implanted in Poland, with an 
advantage of CRT-Ds (87%) over CRT-Ps (13%). In 69.4% 
of patients receiving CRT-D the clinical indication for the 
implantation was CHF with wide QRS. On the other hand, 
70.3% of patients referred for CRT-P had a pacemaker indi-
cation with an expected high percentage of RV pacing. The 
main differences between CRT-D and CRT-P subgroups are 
presented in Table 1. In Poland, the mean age of the patients 
was 67.7 ± 9.7 years compared to 68.6 ± 10.9 years in 
all other countries (median 68 and 70 years, respectively, 
p < 0.00001). The majority of patients receiving CRT were 
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men (Fig. 1). Additionally, 47% of the total European group 
had an HF hospitalisation during the previous year.
There were substantial differences in primary aetiology of 
HF in Polish patients compared to patients from other coun-
tries (Fig. 2). More detailed data from the survey revealed that 
in Poland there were also a greater number of patients with 
a history of myocardial infarction and prior revascularisation 
(percutaneous coronary intervention or coronary artery bypass 
grafting; Table 2) [12].
The EuroHeart Survey showed that persistent and 
permanent atrial fibrillation (AF) account for approximately 
51% of AF [13]. In the European CRT Survey II, patients with 
diagnosed AF formed a large part of the cohort — 43.8% 
in Poland and 40.5% in all other countries, with the rates 
of persistent and permanent forms at 55.1% and 67.0%, 
respectively (p = 0.00024).
Patients with CHF tended to have several comorbidi-
ties. The management of these is often crucial for successful 
HF treatment. The major comorbidities occurring in patients 
with HF and an implanted CRT device are presented in Table 3.
Apart from demographic data and clinical status, another 
area of interest presented in the European CRT Survey II is 
indications for device implantation according to the ESC guide-
lines. The clinical indications for CRT are presented in Table 4. 
Table 1. Characteristics of cardiac resynchronisation therapy-defibrillator (CRT-D) and cardiac resynchronisation therapy-pacemaker 
(CRT-P) recipients in Poland
CRT-D (n = 1137) CRT-P (n = 115) p
Mean age [years] 66.6 ± 9.3 74.7 ± 9.7 < 0.00001
Male/female sex 81.7/18.3 77.4/22.6 0.19893
Atrial fibrillation 40.8 57.4 0.00010
Previous pacemaker implantation 8.2 36.1 < 0.00001
Previous ICD implantation 18.2 0 < 0.00001































Figure 1. Sex proportions in the analysed populations 
(p < 0.00001)
Figure 2. Primary heart failure aetiology (p < 0.00001)






Myocardial infarction 48.4 34.7 < 0.00001
Prior revascularisation (PCI/CABG) 51.2 37.3 < 0.00001
Data are shown as percentage. CABG — coronary artery bypass grafting; PCI — percutaneous coronary intervention
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Cardiac resynchronisation therapy is recommended for 
symptomatic patients with HF in NYHA functional class II–IV 
and a wide QRS. In Poland, 67.7% of patients (vs. 59.0% in 
all other countries) met these criteria, due to the presence of 
LV dysfunction and indications for ICD because of wide QRS. 
Additionally, almost 10% of patients in both compared groups 
were referred for CRT due to indication for pacemaker and 
expectation of a high percentage of RV pacing even without 
HF symptoms (NYHA functional class I) (Fig. 3).
Both in Poland and in other countries, LBBB was pre- 
sent in the majority of patients (Fig. 4). Proportions of pa- 
tients with various intrinsic QRS duration are presented in 
Figure 5.
Another parameter of patient evaluation for CRT is LVEF 
(Fig. 6). According to data collected in the survey, the most 
popular imaging method assessing LVEF was echocardiography 
(99.0% of patients in Poland vs. 91.5% in other countries, 
p < 0.00001). However, alternative methods of assessing 
LVEF, such as cardiac magnetic resonance imaging, computed 
tomography scan, and scintigraphy, were also used. In Poland, 
these methods were applied in 1.0% of patients, and in other 
countries this rate was 8.5% (p < 0.05).
Table 3. Major comorbidities occurring in patients with congestive heart failure
Comorbidity Poland Other countries p
Hypertension 68.4 63.3 0.00041
Valvular heart disease 32.3 26.5 0.00002
Obstructive lung disease 10.0 12.3 0.019
Diabetes 37.2 30.7 < 0.00001
Anaemia 14.8 15.1 0.8
Chronic kidney disease (eGFR < 60 mL/min/1.73 m2) 36.0 30.5 0.0078
Data are shown as percentage. eGFR — estimated glomerular filtration rate
Table 4. Clinical indications for cardiac resynchronisation therapy (CRT)
Clinical indication for CRT Poland Other countries p
Heart failure with wide QRS 67.7 59.0 0.0001
Heart failure and indication for ICD 55.5 46.9 0.0001
Pacemaker indication and expected high percentage of RV pacing 22.7 22.8 0.9385
Evidence of mechanical dyssynchrony 14.6 11.1 0.0003


































Figure 3. New York Heart Association (NYHA) class in  
pre-implantation clinical evaluation (p = 0.246)
Figure 4. QRS morphology groups; LBBB — left bundle branch 
block; RBBB — right bundle branch block (p = 0.03336)
www.kardiologiapolska.pl
Indications and demographics in CRT recipients
43
DISCUSSION
Patients included in surveys may differ from those enrolled 
in RCTs due to the distinct methodology of data collection. 
RCTs have strict protocols concerning patient selection, 
inclusion and exclusion criteria, and specified outcomes, 
which is why they include a specific, well-selected group of 
patients. Conversely, surveys gather a vast amount of data 
without limitations, demonstrating a wide range of informa-
tion on selected issues [14].
For Poland, most of the collected data were similar to 
those obtained from other European nations, but there were 
also some differences. Compared to patients enrolled in RCTs, 
Polish patients included in the CRT Survey II were generally 
older, had narrower QRS complexes, higher LVEF, and more 
often had AF. However, there was a similar percentage of 
ischaemic cardiomyopathy and sex proportion [15].
Considering the age of patients included in the survey in 
terms of the World Health Organization definition of elderly, 
CRT is a treatment that mostly refers to older people [16].
In both Poland and other European countries, there was 
a significant difference in the numbers of device implantations in 
women and men. Women are more likely to experience LBBB 
and may benefit from CRT at a shorter QRS duration than men 
[17]. On the other hand, women with HF are older and less likely 
have severely reduced LVEF [18], which might be the reason why 
they are much less often referred for CRT device implantation.
In 2013, the ESC in collaboration with the EHRA clas-
sified cardiac pacing and CRT patients with persistent and 
permanent AF as candidates for CRT in their guidelines for 
the first time. A total of 43.8% patients in Poland and 40.5% 
in all other countries were diagnosed with AF. Persistent and 
permanent AF accounted for more than a half of this group 
[19]. There have been no relevant trials that compared CRT 
to a control group for patients with AF; however, AF has been 
shown to decrease biventricular pacing in CRT due to com-
petition with irregular intrinsic atrioventricular (AV) conduc-
tion [20]. This could possibly diminish the clinical benefits of 
device implantation, because CRT requires a high percentage 
of ventricular pacing to maximise its role in HF therapy. The 
latest guidelines recommend CRT for patients with AF (class 
IIa) and stress the importance of biventricular pacing (as close 
to 100% as can possibly be achieved) either through AV nodal 
ablation or through pharmacotherapy.
Most patients included in the European CRT Survey II 
experienced LBBB and an intrinsic QRS duration longer than 
150 ms. RCTs meta-analyses have shown that the longer the 
patient’s intrinsic QRS duration, the more beneficial the clini-
cal long-term outcome of CRT implantation [21]. Sub-analyses 
of RCTs and meta-analyses have shown that the profitable 
effects of CRT were observed in patients with typical LBBB 
[22]. Some patients (2.9% in Poland, 8.1% in other countries) 
received CRT even though they had a QRS duration shorter 
than 120 ms. Current guidelines based on the ECHO-CRT and 
LESSER-EARTH trials do not recommend implanting CRT in 
such cases because there is no evidence of benefit in patients 
with HF and QRS duration shorter than 120 ms [23, 24].
Both in Poland and in other countries, the majority 
(90.6% and 86.7%, respectively) of patients had an LVEF of less 
than 35%. There are only two trials (REVERSE, BLOCK-HF) that 
enrolled patients with an LVEF greater than 35%. Due to the 
small group of patients included, the results were inconclusive. 
Despite the large number of patients enrolled in the sur-
vey, there were huge differences between countries. In coun-
tries with only one or two participating centres, results may be 
inconclusive for the whole country. Moreover, implanting sites 
may have neglected patients with poor outcome or unsuccess-
ful procedures, because there was no independent monitoring 
of data collection. During the enrolment period of the survey 
the new ESC HF guidelines were published. It is difficult to 
assess their impact on selection and enrolment of patients.
Figure 6. Left ventricular ejection fraction (by any method) 









































Figure 5. Intrinsic QRS duration (p < 0.00001)
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In conclusion, as far as demographic data from the sur-
vey are concerned, it can be generally inferred that patients 
receiving CRT were mainly men with depressed LVEF (mostly 
less than 35%), LBBB, and an intrinsic QRS duration of more 
than 150 ms. This was observed for both Poland and other 
European countries and is in line with the guidance criteria 
for CRT device implantation.
On the other hand, some devices were implanted in 
patients with a relatively narrow QRS complex, patients with 
non-LBBB, and patients with LVEF over 35%. For these indi-
cations, guideline recommendations are weak and levels of 
evidence are low, and the decision regarding CRT implantation 
relies mainly on the physicians’ experience.
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